Literature DB >> 6089568

Pituitary adenomas. An immunohistochemical study of hormone production and chromogranin localization.

D B DeStephano, R V Lloyd, A M Pike, B S Wilson.   

Abstract

Tumors from 42 surgically resected pituitaries and from 13 autopsy cases were studied immunohistochemically with polyclonal antisera to 7 anterior pituitary hormones and with a newly developed monoclonal antibody directed against human chromogranin for evaluation of the distribution of chromogranin in normal and neoplastic pituitaries. In addition, a prospective study was done for assessment of the prevalence, morphology, and endocrine cell types of pituitary tumors in 100 autopsy subjects. When these 55 pituitary adenomas were examined with monoclonal antibody (LK2H10) directed against human chromogranin, selective staining of normal adenohypophyseal cell types and pituitary tumors was observed. Most null-cell adenomas (12/14) were positive for chromogranin, whereas all prolactin (PRL)-producing adenomas (19/19) were negative. Growth hormone (GH) adenomas were focally positive (9/9). All oncocytomas (2/2), 1 thyrotropin (TSH) adenoma, and a follicle-stimulating hormone/luteinizing hormone adenoma were positive for chromogranin. One or more adenomas were present in 14% of the autopsy cases. The tumors occurred most frequently in patients in the fifth through the seventh decades of life. Immunohistochemical staining of 13 adenomas revealed 1 TSH, 1 ACTH, and 4 PRL-producing tumors, whereas 7 other tumors, which were null-cell or undifferentiated adenomas, failed to stain for any of the seven principle pituitary hormones. These results indicate that antibody LK2H10 to human chromogranin is useful in the immunohistochemical characterization of pituitary adenomas. Incidental pituitary microadenomas from autopsy-derived pituitaries most commonly produce PRL, or they belong to the null-cell or undifferentiated tumor group.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6089568      PMCID: PMC1900471     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

Review 1.  Ultrastructure of human sella tumors. Correlations of clinical findings and morphology.

Authors:  A M Landolt
Journal:  Acta Neurochir (Wien)       Date:  1975       Impact factor: 2.216

Review 2.  Pituitary adenomas.

Authors:  K Kovacs; E Horvath; C Ezrin
Journal:  Pathol Annu       Date:  1977

3.  Absence of chromophobe adenomas from a large series of pituitary tumors.

Authors:  W F McCormick; N S Halmi
Journal:  Arch Pathol       Date:  1971-10

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Specific endocrine tissue marker defined by a monoclonal antibody.

Authors:  R V Lloyd; B S Wilson
Journal:  Science       Date:  1983-11-11       Impact factor: 47.728

6.  Natural history of microprolactinomas: six-year follow-up.

Authors:  M H Weiss; J Teal; P Gott; R Wycoff; R Yadley; M L Apuzzo; S L Giannotta; O Kletzky; C March
Journal:  Neurosurgery       Date:  1983-02       Impact factor: 4.654

Review 7.  Pituitary prolactinomas.

Authors:  J D Nabarro
Journal:  Clin Endocrinol (Oxf)       Date:  1982-08       Impact factor: 3.478

8.  Pituitary adenomas in old age.

Authors:  K Kovacs; N Ryan; E Horvath; W Singer; C Ezrin
Journal:  J Gerontol       Date:  1980-01

9.  Localization of prolactin in chromophobe pituitary adenomas: study of human necropsy material by immunoperoxidase technique.

Authors:  K Kovacs; B Corenblum; A M Sirek; G Penz; C Ezrin
Journal:  J Clin Pathol       Date:  1976-03       Impact factor: 3.411

10.  Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues.

Authors:  D T O'Connor; D Burton; L J Deftos
Journal:  J Clin Endocrinol Metab       Date:  1983-11       Impact factor: 5.958

View more
  14 in total

Review 1.  Human pituitary adenomas. Recent advances in morphological studies.

Authors:  G Giannattasio; M Bassetti
Journal:  J Endocrinol Invest       Date:  1990-05       Impact factor: 4.256

Review 2.  The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors.

Authors:  P Rosa; H H Gerdes
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

3.  Immunohistochemical evaluation of the post-translational processing of chromogranin A in human pituitary adenomas.

Authors:  A P Heaney; W J Curry; K M Pogue; V L Armstrong; M Mirakhur; B Sheridan; C F Johnston; K D Buchanan; A B Atkinson
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

4.  Human brain cancer studied by resonance Raman spectroscopy.

Authors:  Yan Zhou; Cheng-Hui Liu; Yi Sun; Yang Pu; Susie Boydston-White; Yulong Liu; Robert R Alfano
Journal:  J Biomed Opt       Date:  2012-11       Impact factor: 3.170

5.  Immunohistochemical study of chromogranin in 100 cases of pheochromocytoma, carotid body tumour, medullary thyroid carcinoma and carcinoid tumour.

Authors:  N Kimura; N Sasano; R Yamada; J Satoh
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

Review 6.  The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia.

Authors:  Steven A Feldman; Lee E Eiden
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

7.  Chromogranin a processing in human pituitary adenomas and carcinomas: analysis with region-specific antibodies.

Authors:  Long Jin; Shuya Zhang; Jill Bayliss; Bernd Scheithauer; Xiang Qian; Ikuo Kobayashi; Mats Stridsberg; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

8.  Pituitary oncocytomas: clinical features, characteristics in cell culture, and treatment recommendations.

Authors:  D L Silbergeld; M R Mayberg; M S Berger; F Ali-Osman; W A Kelly; C M Shaw
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

9.  Chromogranin A expression in normal and malignant human tissues.

Authors:  L J Helman; A F Gazdar; J G Park; P S Cohen; J D Cotelingam; M A Israel
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

10.  Clinically nonfunctioning pituitary tumors are monoclonal in origin.

Authors:  J M Alexander; B M Biller; H Bikkal; N T Zervas; A Arnold; A Klibanski
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.